BRCA1, Monoclonal Antibody

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG1

6B4

Mouse

Purified
Purified IgG - liquid

IgG concentration 1.0 mg/ml (lot specific)

Store at 4 degree C or at -20 degree C if preferred. This product should be stored undiluted. Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life: 18 months from date of despatch

Small volumes of anti-BRCA1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Mouse anti BRCA1 antibody, clone 6B4 recognizes both human and mouse BRCA1, otherwise known as breast cancer type 1 susceptibility protein, a tumor suppressor gene and major player in DNA damage repair, predominantly expressed in the nucleus during the S/G2 phase of the cell cycle. Along with BRCA2, BRCA1 is a high risk gene which is associated with hereditary breast and ovarian cancers, particularly at a younger age of diagnosis. Women carrying the BRCA1 mutation have a 50-95% chance of developing breast cancer in later life, but genetic screening and increased awareness of preventative surgery, can reduce this risk significantly. Deleterious BRCA1 mutations may also increase the risk of other cancers in both males and females including pancreatic cancer, although in males pancreatic and prostate cancer appear to be more strongly associated with BRCA2 gene mutations. BRCA1 is a key marker of triple-negative breast cancer/TNBC (ER-/PR-/HER2-), a high risk aggressive cancer which makes up about 15% of invasive breast cancers, and which lacks the benefit of specific therapy that targets the three major proteins ER/PR/HER2. Triple-negative tumors are predominantly basal-like, poorly differentiated and of higher histological grade. Younger women have an increased rate of basal or BRCA related TNBC, compared with the higher proportion of apocrine, normal-like and rare subtypes of TNBC, seen in older women. Mouse anti BRCA1, clone 6B4 recognises full length 220kDa BRCA1, but does not recognize the delta11b splice variant. The breast milk cell line HBL100 can be used as a positive control.

Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistology Paraffin, Western Blot (WB)

Immunofluorescence: Maximum Dilution: 1/400;
Western Blotting: Minimum Dilution: 1/250; Maximum Dilution: 1/1000

210,266 Da

breast cancer 1, early onset

breast cancer type 1 susceptibility protein; BRCA1/BRCA2-containing complex, subunit 1; Fanconi anemia, complementation group S; RING finger protein 53; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein 1; protein phosphatase 1, regulatory subunit 53

Breast cancer type 1 susceptibility protein

RNF53  [Similar Products]

BRCA1_HUMAN

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009]

BRCA1: the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACC1 and preventing its dephosphorylation. Defects in BRCA1 are a cause of genetic susceptibility to breast cancer. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association may be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts (via BRCT domains) with CTIP. Associates with RNA polymerase II holoenzyme. Interacts with SMC1 and COBRA1. Interacts (via BRCT domains) with BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with Artemis and claspin. Interacts with H2AFX (phosphorylated on S140). Interacts with CHK1. Interacts with BRCC3. Five human isoforms are produced by alternative splicing and alternative initiation. Isoform 1 and isoform 3 are widely expressed. Isoform 1 is largely nuclear, while isoforms 3 and 5 are cytoplasmic.

Protein type: Transcription, coactivator/corepressor; Nuclear receptor co-regulator; Ubiquitin conjugating system; Tumor suppressor; Ubiquitin ligase; EC 6.3.2.-

Chromosomal Location of Human Ortholog: 17q21

Cellular Component: nucleoplasm; gamma-tubulin ring complex; protein complex; condensed nuclear chromosome; BRCA1-BARD1 complex; cytoplasm; plasma membrane; chromosome; ribonucleoprotein complex; nucleus; ubiquitin ligase complex

Molecular Function: tubulin binding; protein binding; enzyme binding; DNA binding; androgen receptor binding; zinc ion binding; RNA binding; ubiquitin protein ligase binding; transcription coactivator activity; ubiquitin-protein ligase activity; damaged DNA binding; ligase activity

Biological Process: genetic imprinting; apoptosis; positive regulation of transcription, DNA-dependent; dosage compensation, by inactivation of X chromosome; centrosome cycle; protein ubiquitination; negative regulation of histone H3-K4 methylation; positive regulation of histone H3-K4 methylation; negative regulation of histone acetylation; chromosome segregation; regulation of apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; double-strand break repair; DNA replication; fatty acid biosynthetic process; negative regulation of fatty acid biosynthetic process; negative regulation of histone H3-K9 methylation; positive regulation of histone H3-K9 methylation; protein autoubiquitination; chordate embryonic development; positive regulation of DNA repair; postreplication repair; DNA repair; negative regulation of centriole replication; double-strand break repair via homologous recombination; regulation of cell proliferation; regulation of transcription from RNA polymerase II promoter; positive regulation of angiogenesis; DNA damage response, signal transduction resulting in induction of apoptosis; regulation of transcription from RNA polymerase III promoter; positive regulation of protein ubiquitination; response to estrogen stimulus; androgen receptor signaling pathway; positive regulation of histone acetylation; positive regulation of transcription from RNA polymerase II promoter; response to ionizing radiation; negative regulation of transcription, DNA-dependent; G2/M transition DNA damage checkpoint; response to DNA damage stimulus

Disease: Breast-ovarian Cancer, Familial, Susceptibility To, 1; Pancreatic Cancer, Susceptibility To, 4; Breast Cancer

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.